Always needed to break into the medical community through word...

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 52 Last

Share
Profile

Follow
AlCp

27,466 Posts.

1781

01/09/20

17:18

Post #: 46996856
Share

Originally posted by ChampKind01 ↑

Agreed @Chuckybee

The IP gathered over the past 3 months and that which will be collected during the extended period will be invaluable.
Not just with respect to the resappdx-eu algorithm and the underlying cough signature catalogue, but also evidence of integration within the workflow of a real world clinical setting.

The recent experience should have provided Resapp IT, Product Development and Business Development staff with critical insight(s) into the systems integration requirements and physical processes being used to manage patient flow within clinical and emergency response settings.

For those not familiar with B2B IT systems integration, it is not uncommon for the vendor to be tasked with identifying and/or providing suggested solutions to barriers to integration within the purchasers IT system(s) and physical processes, in order to get things across the line. It can be a slow process to join the dots, test and release and train. This IP goes straight into Resapp integration playbook for future reference.

With this in mind, Morayfield Clinic can have this at $0 for as long as they want (IMO), providing Resapp are yielding valuable IP, developing industry contacts and being provided with testimony (good, bad or indifferent) from Dr Evan Jones and his team.

Upon reflection, if we let the words "once in a 100 year global pandemic" sink in, we are actually dam lucky to have had this opportunity with the Morayfield Clinic. How many other established clinical settings would have let a new diagnostic tool anywhere near there current patient workflow....?

All IMO, but truth be told I still have NFI.

Expand

Always needed to break into the medical community through word of mouth for clinic and hospital (but not much so for telehealth as clinician have no other option but to use ResAppDx if they wanted to do remote respiratory consultation).

"The continued use of ResAppDx in the clinic is providing us with valuable real-world evidence on the benefits of ResAppDx, and the clinic has additionally agreed to share and publish this evidence with the medical community"

RAP Price at posting: 12.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

What's causing the cost-of-living crisis, and how to navigate it

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins